GPX 150

Drug Profile

GPX 150

Alternative Names: 5-imino-13-deoxy-doxorubicin HCl; CNDO-101; GPX150

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gem Pharmaceuticals
  • Developer Monopar Therapeutics
  • Class Antineoplastics; Doxorubicins
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Soft tissue sarcoma
  • Phase I Cancer; Solid tumours
  • Preclinical Psoriasis

Most Recent Events

  • 14 Nov 2017 Monopar Therapeutics acquired GPX-150 from Gem Pharmaceuticals
  • 14 Nov 2017 Adverse events and efficacy data from a phase I trial in Solid tumours released by Monopar Therapeutics
  • 06 Sep 2017 GPX 150 is still in phase II development for Soft tissue sarcoma (Metastatic disease) in USA (IV) (Gem Pharmaceuticals pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top